Information Provided By:
Fly News Breaks for August 18, 2015
BIIB
Aug 18, 2015 | 08:21 EDT
After meeting with Biogen's management, RBC Capital likes the stock's risk/reward ratio, as it believes that the company's Alzheimer's drugs and other pipeline drugs could cause the stock to rally 50%-100%. The firm notes that the company's management is buying stock, and it thinks that the company "would become a much more talked about M&A candidate" if its stock stays near current levels. RBC keeps a $450 price target and Outperform rating on the shares.
News For BIIB From the Last 2 Days
There are no results for your query BIIB